Association between sRAGE, esRAGE levels and vascular inflammation: Analysis with 18F-fluorodeoxyglucose positron emission tomography

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 402-406

  Yang, Sae Jeong ^a   Kim, Sungeun ^a   Hwang, Soon Young ^a   Kim, Tae Nyun ^b   Choi, Hae Yoon ^a   Yoo, Hye Jin ^a   Seo, Ji A ^a   Kim, Sin Gon ^a   Kim, Nan Hee ^a   Baik, Sei Hyun ^a   Choi, Dong Seop ^a   Choi, Kyung Mook ^a  

^a Korea University College of Medicine   (South Korea)

^b Inje University   (South Korea)

Author keywords

Atherosclerosis; Inflammation; Positron emission tomography; RAGE; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ENDOGENOUS SECRETORY ADVANCED GLYCATION END PRODUCT RECEPTOR; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN A1C; MEMBRANE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEX DIFFERENCE; VASCULITIS;

AGED; BIOLOGICAL MARKERS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FLUORODEOXYGLUCOSE F18; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECEPTORS, IMMUNOLOGIC; REGRESSION ANALYSIS; REPUBLIC OF KOREA; UP-REGULATION;

EID: 84855951223     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.008     Document Type: Article

References (30)

1. Kume N. Molecular mechanisms of coronary atherosclerotic plaque formation and rupture. Nippon Rinsho 2010, 68:637-641.
2. 18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002, 105:2708-2711.
3. 18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 2007, 49:1533-1539.
4. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006, 48:1825-1831.
5. Kim T.N., Kim S., Yang S.J., et al. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging 2010, 3:142-148.
6. 18F-fluorodeoxyglucose positron emission tomography. Arterioscler Thromb Vasc Biol 2011.
7. 18F-fluorodeoxyglucose positron emission tomography. J Clin Endocrinol Metab 2010.
8. 18F-FDG PET. J Nucl Med 2010, 52:10-17.
9. Yan S.F., Ramasamy R., Schmidt A.M. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010, 79:1379-1386.
10. Csiszar A., Ungvari Z. Endothelial dysfunction and vascular inflammation in type 2 diabetes: interaction of AGE/RAGE and TNF-alpha signaling. Am J Physiol Heart Circ Physiol 2008, 295:H475-H476.
11. Santilli F., Vazzana N., Bucciarelli L.G., Davi G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 2009, 16:940-952.
12. Lanati N., Emanuele E., Brondino N., Geroldi D. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr Vasc Pharmacol 2010, 8:86-92.
13. Choi K.M., Yoo H.J., Kim H.Y., et al. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 2009, 132:96-101.
14. Standards of medical care in diabetes - 2010. Diabetes Care 2009, 33:S11-S61.
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
16. Kim S.M., Lee J., Ryu O.H., et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf) 2005, 63:594-598.
17. 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008, 49:871-878.
18. Vazzana N., Santilli F., Cuccurullo C., Davi G. Soluble forms of RAGE in internal medicine. Intern Emerg Med 2009.
19. Ramasamy R., Yan S.F., Herold K., Clynes R., Schmidt A.M. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann NY Acad Sci 2008, 1126:7-13.
20. Lindsey J.B., de Lemos J.A., Cipollone F., et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the dallas heart study. Diabetes Care 2009, 32:1218-1220.
21. Catalano M., Cortelazzo A., Santi R., et al. The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (receptor for advanced glycation endproducts) and the presence of peripheral arterial disease. Clin Biochem 2008, 41:981-985.
22. Lu L., Jin Pu L., Chen Q.J., et al. Increased glycated albumin and decreased esRAGE concentrations are associated with in-stent restenosis in Chinese diabetic patients. Clin Chim Acta 2008, 396:33-37.
23. Katakami N., Matsuhisa M., Kaneto H., et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2009, 204:288-292.
24. Silvera S.S., Aidi H.E., Rudd J.H., et al. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis 2009, 207:139-143.
25. Ogawa M., Ishino S., Mukai T., et al. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 2004, 45:1245-1250.
26. 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006, 48:1818-1824.
27. Basta G., Sironi A.M., Lazzerini G., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006, 91:4628-4634.
28. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2587-2593.
29. Norata G.D., Garlaschelli K., Grigore L., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 2009, 19:129-134.
30. Tan K.C., Shiu S.W., Chow W.S., Leng L., Bucala R., Betteridge D.J. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006, 49:2756-2762.